Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …

Newer radio-tracer shows potential in imaging of recurrent prostate cancer

Data have been emerging for a while to suggest that a new imaging agent known as anti-3-[18F]FACBC (when used in PET/CT scans may be better than [11C]choline in the identification of recurrent (or primary) cancers on PET/CT scans or than older agents like [111In]capromab pendetide (Prostascint) when used in SPECT/CT scans. … READ MORE …

Use of imaging tests in low-risk prostate cancer — striking the right balance

An article published a couple of weeks ago in the Journal of the National Cancer Institute looks at the effects of a physician education campaign in Sweden to reduce the inappropriate use of bone scans and other imaging tests among men with an initial diagnosis of low-risk prostate cancer. … READ MORE …

“Multispectral photoacoustic imaging” for risk of prostate cancer

According to a media release issued earlier today by the University of Rochester Medical Center, “A new imaging technology that combines ultrasound and laser technologies has been shown to be highly effective in identifying prostate cancer.” … READ MORE …

mpMRI in diagnosis and management of prostate cancer tomorrow

A new review article in Oncology discusses the potential of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and management of prostate cancer, and will be useful reading for many advocates and support group leaders. … READ MORE …

MRI-guided biopsies growing more common … but can we deal with the cost?

According to an article published on the Medscape Oncology web site earlier today, two paper presented at the European Congress of Radiology have provided further evidence of the potential of MRI-guided biopsies in the diagnosis of prostate cancer. … READ MORE …

New targeted imaging agents and the diagnosis, prognosis of progressive disease

According to a media release issued today by Progenics Pharmaceuticals, early clinical studies of two of their investigational products — the imaging agents [123I]-MIP-1072 and [123I]-MIP-1095 — suggest potential of these two agents in enhancement of imaging techniques to identify the exact location of cancer in bone, tissue, and the prostate itself. … READ MORE …

More on [11C]choline PET/CT scanning in men with recurrent prostate cancer

A new article just published on line in the Journal of Urology offers additional information about the “operational characteristics” of [11C]choline PET/CT scanning in the diagnosis of biochemically recurrent prostate cancer after first-line treatment (a technique currently available only at the Mayo Clinic in Rochester, MN). … READ MORE …

The accuracy (and value) of MRI methods in diagnosis and prognosis of prostate cancer

Two recent studies are helpful in clarifying the issue of when specific types of magnetic resonance imaging (MRI) meothds may be useful in the diagnosis and prognosis of prostate cancer. … READ MORE …

Accurate identification of positive lymph nodes in men with progressive prostate cancer

One of the hardest things to be able to do, currently, in a man with progressive prostate cancer after first- or second-line therapy, is to determine his risk for lymph node-positive prostate cancer or LNPPC (i.e., one of the earliest  and more common components of metastatic prostate cancer). … READ MORE …

Intraoperative, tumor-specific fluorescence imaging — will it work in prostate cancer?

A report just published on line in Nature Medicine describes the first use of intraoperative, tumor-specific fluorescence imaging to highlight the precise position of small groups of cancer cells in women with ovarian cancer, thereby allowing the surgeon to carefully excise such small groups of cells. … READ MORE …

New imaging technologies and management of CRPC

An article in the June issue of the journal Acta Oncologia discusses the potential of  newer types of imaging technology as methods to monitor the progression of disease in men with castrate-resistant prostate cancer (CRPC). … READ MORE -

A new (and better?) prostate cancer-specific imaging agent

With the failure of Combidex (ferumoxtran-10) to achieve FDA approval as an imaging agent for  lymph node-positive prostate cancer and the recognized limitations of the ProstaScint (capromab pendetide) scan, there is a widely acknowledged need for a much more specific and accurate prostate cancer imaging agent than anything currently available. … READ MORE …

Is Trofex a possible “replacement” imaging agent for Combidex?

According to a media release issued on Thursday this week by Molecular Insight Pharmaceuticals, Inc. (MIP), an investigational imaging agent known as Trofex™ (a.k.a, 123I-MIP-1072) may offer a new opportunity to identify the presence of early signs of metastatic prostate cancer in the prostate bed, soft tissues, and bone within 4 hours after injection. … READ MORE …

Prostate cancer news reports: Monday, July 26, 2010

There are several interesting new publications worth commenting on this morning — all in the evolving research field as opposed to current clinical practice:

  • Angiogenic effect of a specific statin on prostate cancer development
  • Synergistic impact of calcitriol on cryotherapy
  • Hybrid imaging techniques and prostate cancer
  • GTI-2040 in treatment of CRPC … READ MORE …
Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers